illustration drugs running

HemaXis™ DB10 samples professional cyclists in drug monitoring program

DBS System SA today announced its collaboration with the Union Cycliste Internationale (UCI) and the Center of Research and Expertise in anti-Doping sciences (REDs) to monitor the use of Tramadol in the professional peloton. Following the ban of Tramadol use on March 1, the drug has been tested on 143 samples of 117 professional riders at 11 major events on the UCI WorldTour Calendar.

Blood samples have been collected with HemaXis™ DB10, the patented blood collection device manufactured by DBS System SA, a company based in Switzerland. HemaXis DB10 generates reliable blood microsamples straight from the rider’s finger-tip in an instantaneous, user-friendly and cost-effective manner.

HemaXis™ uniquely allows the convenient collection and storage of an accurate quantity of blood in the form of dried blood spots. These standardized dried blood spots enable a dependable analysis, while reducing overall cost and logistic constraints.

“We are proud to announce that HemaXis™ contributes to the health and safety of the competitors.” said Eric Ödman, CEO of DBS System. “We firmly believe that our technology will be the way forward for much improved monitoring of drug use in sport.”

UCI press release available at